Person:
YAMAÇ, AYLİN HATİCE

Loading...
Profile Picture
Google ScholarScopusORCIDPublons
Status
Kurumdan Ayrılmıştır
Organizational Units
Organizational Unit
Job Title
First Name
AYLİN HATİCE
Last Name
YAMAÇ
Name
Email Address
Birth Date

Search Results

Now showing 1 - 2 of 2
  • PublicationMetadata only
    SARS-CoV-2 Positivity, Stent Thrombosis, and 30-day Mortality in STEMI Patients Undergoing Mechanical Reperfusion
    (2022-10-01T00:00:00Z) De Luca, Giuseppe; Algowhary, Magdy; Uguz, Berat; Oliveira, Dinaldo C.; Ganyukov, Vladimir; Zimbakov, Zan; Cercek, Miha; Jensen, Lisette Okkels; Loh, Poay Huan; Calmac, Lucian; Ferrer, Gerard Roura; Quadros, Alexandre; Milewski, Marek; Di Uccio, Fortunato Scotto; von Birgelen, Clemens; Versaci, Francesco; Ten Berg, Jurrien; Casella, Gianni; Lung, Aaron Wong Sung; Kala, Petr; Gil, Jose Luis Diez; Carrillo, Xavier; Dirksen, Maurits; Becerra-Munoz, Victor M.; Lee, Michael Kang-Yin; Juzar, Dafsah Arifa; Joaquim, Rodrigo de Moura; De Simone, Ciro; Milicic, Davor; Davlouros, Periklis; Bakraceski, Nikola; Zilio, Filippo; Donazzan, Luca; Kraaijeveld, Adriaan; Galasso, Gennaro; Arpad, Lux; Marinucci, Lucia; Guiducci, Vincenzo; Menichelli, Maurizio; Scoccia, Alessandra; Yamac, Aylin Hatice; MERT, KADİR UĞUR; Rios, Xacobe Flores; Kovarnik, Tomas; Kidawa, Michal; Moreu, Jose; Flavien, Vincent; Fabris, Enrico; Martinez-Luengas, Inigo Lozano; Boccalatte, Marco; Ojeda, Francisco Bosa; Arellano-Serrano, Carlos; Caiazzo, Gianluca; Cirrincione, Giuseppe; Kao, Hsien-Li; Fores, Juan Sanchis; Vignali, Luigi; Pereira, Helder; Manzo-Silbermann, Stephane; Ordonez, Santiago; Ozkan, Alev Arat; Scheller, Bruno; Lehtola, Heidi; Teles, Rui; Mantis, Christos; Antti, Ylitalo; Silveira, Joao Antonio Brum; Bessonov, Ivan; Zoni, Rodrigo; Savonitto, Stefano; Kochiadakis, George; Alexopoulos, Dimitrios; Uribe, Carlos E.; Kanakakis, John; Faurie, Benjamin; Gabrielli, Gabriele; Barrios, Alejandro Gutierrez; Bachini, Juan Pablo; Rocha, Alex; Tam, Frankie Chor-Cheung; Rodriguez, Alfredo; Lukito, Antonia Anna; Bellemain-Appaix, Anne; Pessah, Gustavo; Cortese, Giuliana; Parodi, Guido; Burgadha, Mohammed Abed; Kedhi, Elvin; Lamelas, Pablo; Suryapranata, Harry; Nardin, Matteo; Verdoia, Monica; YAMAÇ, AYLİN HATİCE
    SARS-Cov-2 has been suggested to promote thrombotic complications and higher mortality. The aim of the present study was to evaluate the impact of SARS-CoV-2 positivity on in-hospital outcome and 30-day mortality in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) enrolled in the International Survey on Acute Coronary Syndromes ST-segment elevation Myocardial Infarction (ISACS-STEMI COVID-19 registry. The 109 SARS-CoV-2 positive patients were compared with 2005 SARS-CoV-2 negative patients. Positive patients were older (P = .002), less often active smokers (P = .002), and hypercholesterolemic (P = .006), they presented more often later than 12 h (P = .037), more often to the hub and were more often in cardiogenic shock (P = .02), or requiring rescue percutaneous coronary intervention after failed thrombolysis (P < .0001). Lower postprocedural Thrombolysis in Myocardial Infarction 3 flow (P = .029) and more thrombectomy (P = .046) were observed. SARS-CoV-2 was associated with a significantly higher in-hospital mortality (25.7 vs 7%, adjusted Odds Ratio (OR) [95% Confidence Interval] = 3.2 [1.71-5.99], P < .001) in-hospital definite in-stent thrombosis (6.4 vs 1.1%, adjusted Odds Ratio [95% CI] = 6.26 [2.41-16.25], P < .001) and 30-day mortality (34.4 vs 8.5%, adjusted Hazard Ratio [95% CI] = 2.16 [1.45-3.23], P < .001), confirming that SARS-CoV-2 positivity is associated with impaired reperfusion, with negative prognostic consequences.
  • PublicationOpen Access
    Outcomes in Coronary No Reflow Phenomenon Patients and the Relationship between Kidney Injury Molecule-1 and Coronary No-Reflow Phenomenon
    (2021-02-01T00:00:00Z) Huyut, Mustafa Ahmet; YAMAÇ, AYLİN HATİCE; YAMAÇ, AYLİN HATİCE
    Background: Coronary no-reflow phenomenon (CNP) is associated with an increased risk of major cardiovascular adverse events (MACE).